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Response to “Re: The Awakening of Alice”
It was with great interest that I read the various comments
from Jean-Pierre Becquemin and his colleagues in response to
our recent editorial.1,2 I agree with the authors that it is oc-
casionally difﬁcult to match results produced from high-
volume expert centers in the “real world”. Examples include
the “Bolia subintimal angioplasty technique” or (more rele-
vant to this debate) the results of open thoracoabdominal
aortic aneurysm (TAAA) surgery. However, it is still our pri-
mary task to provide the best possible patient care, especially
in pathologies that require more complex surgery.
If one wishes to embark on treating TAAAs with fenes-
trated and/or branched grafts, a number of prerequisites are
necessary. These include (i) dedicated surgeons who want to
invest in these techniques in order to acquire much-needed
expertise; (ii) perfect organization with regard to logistics,
including access to a hybrid room; and (iii) the creation of a
professional team, including anesthesiologists and nurses.
While I agree that not all of these prerequisites require a
high-volume center, there should be no doubt that this type
of complex pathology is best treated in large-volume centers.
There is simply no place for amateur behaviour or inexperi-
enced operators, as even minor technical errors can be costly
to the patient, as we have all experienced.
Pioneers have to take new techniques forward and should
report their results. In order to help others move forward,
we fully agree with the authors that these reports should
provide more detail regarding indications, limitations and
lessons learned. Fenestrated endovascular aortic aneurysmrepair (FEVAR) has become a standardized technique in our
center, with low mortality and excellent midterm results. We
also agree that follow-up should be enforced, and the fact
that so many patients were not followed up in the Windows
trial could be interpreted as a lack of organization and
dedication. Our paper on 10 years of experience in TAAA
branched grafting concluded that “too high-risk” patients
should not be treated at all. Indeed, the highest-risk patients
had a higher early mortality and lower survival.3 We also
agree that patients who are unlikely to survive for 2 years
after their surgery will not (by deﬁnition) have beneﬁtted
from the repair. Our conclusion in that article was meant to
help other centers. Obviously, it is difﬁcult for surgeons to
deny a patient treatment when he or she has been referred
as “a last resort”, but we have to learn from experience and
help others not to make the same mistakes.
It was a little disappointing that the authors considered
our published work to be of lower evidential quality
(compared with the Windows trial). They have reported that
there was no statistical difference in mortality between the
two high-volume and the other ﬁve centers in the Windows
trial, but (by their own criteria) this type of post-hoc anal-
ysis is also “lower-quality evidence” as the numbers are too
small to enable any meaningful comparison. A non-
inferiority study would require about 600 patients in each
arm to prove that the lack of difference was not due to a
type II error. In other words, the Windows Registry was
never powered to prove this statistical difference.
Our caveat emptor editorial was intended to warn col-
leagues about problems associated with uncritically devel-
oping endovascular programmes for treating complex TAAAs
and to motivate them to invest more in organization, logistics,
and team approaches. Dedicated endovascular teams can
perform standard FEVAR after thorough training, even in
lower-volume centers. However, for triple and quadruple
FEVAR cases, the imaging requirements are clearly higher
(longer ﬂuoroscopy times, including lateral viewing) and the
operative risks inevitably increase. For cases of branched TAAA,
all of the prerequisites discussed above should bemet in order
to address numerous potential intraoperative complications. It
is, therefore, shameful that politics and/or professional orga-
nizations are not able (or unwilling) to promote the centrali-
zation of treatment for patients with complex aortic pathology.
As Holt and Thompson recently stated: “if we fail to centralize
complex aortic pathology, we will have failed our patients”.4
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Re: ‘Prothrombin G20210 Mutation and Lower Extremity
Peripheral Arterial Disease: A Systematic Review and
Meta-analysis’
Vasquez et al.1 showed that prothrombin G20210 mutation
is signiﬁcantly elevated in patients with peripheral occlusive
arterial disease (POAD) suffering from critical limb ischemia
(CLI) but not in the others. Interestingly, this mutation has
been reported to be more prevalent in patients with
Buerger’s disease.2,3 Avcu et al.2 found an increased fre-
quency of the G20210 mutation in Buerger’s disease (OR
7.98, 2.45e25.13). Buerger’s disease is characterized by
diffuse arterial thrombosis and a severe clinical picture,
most often at the CLI stage. In a recently published case
control study among patients with premature POAD the
author’s team found that G20210 mutation was signiﬁcantly
more frequent in Buerger’s disease (4.2% vs. 1.7 in con-
trols).3 This difference was not found for atherosclerosis
related POAD (2.6%). When compared with the 64 POAD
patients, the 49 with Buerger’s disease had CLI in 88%
versus 28% in atherosclerosis related POAD. As suggested
by Vasquez et al.,1 G20210 mutation might be one among
several factors favouring thrombosis and leading to CLI in
POAD, and prospective cohort studies would be useful to
evaluate the role of this mutation to predict progression in
POAD.
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Response to ‘Re: Prothrombin G20210A Mutation and
Lower Extremity Peripheral Arterial Disease. A Systematic
Review and Meta-analysis’
We read with interest the letter by Boulon et al.1 The pro-
posed association between prothrombin G20210A and
thromboangiitis obliterans is very interesting. Prior studies
have suggested that prothrombin G20210A interacts with
other cardiovascular risk factors (especially smoking) to in-
crease the risk of vascular events,2 and this interaction could
further explain the association of prothrombin G20210A and
thromboangiitis obliterans seen by Bérard et al. and Avcu et
al.3,4 The literature search conducted in our systematic re-
view did not identify the study by Bérard et al.3,5; had the
study been included there would have been no changes in
the association of lower extremity peripheral arterial disease
(PAD) prothrombin G20210A (pooled random effect odds
ratio 1.68 [95% conﬁdence interval 0.94e3.00]; I2 52.1%; p
¼ .08). Furthermore, the addition of the study by Bérard et
al. does not modify the association between prothrombin
G20210A and critical limb ischemia secondary to PAD (even
in the absence of positive cases).3 Finally, we agree that
well-designed prospective cohort studies are needed to
evaluate the role of prothrombin G20210A in the progres-
sion and outcome of patients with PAD.
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